Hereditary transthyretin amyloidosis with a previously undescribed variant p.Tyr89Phe (Tyr69Phe) in the TTR gene

Aksenova YuO, Nasonova SN, Zhirov IV, et al. . Hereditary transthyretin amyloidosis with a previously undescribed variant p.Tyr89Phe (Tyr69Phe) in the TTR gene. Russian Cardiology Bulletin. 2023;18(2):80‑87. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20231802180

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Clinical and genetic associations in patients with non-cardioembolic ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):12-19

Abstract:

The authors present a patient with hereditary transthyretin amyloidosis associated with a nucleotide sequence in the TTR gene responsible for this disease and not previously described in the literature. Clinical manifestations of disease were compared with diagnostic data in family members.

Keywords:

amyloidosis

transthyretin

hereditary

pathogenicity

variant

gene

Authors:

Aksenova Yu.O.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0002-6546-2535

Nasonova S.N.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0002-0920-7417

Zhirov I.V.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0002-4066-2661

Ansheles A.A.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0002-2675-3276

Dobrovolskaya S.V.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0003-0580-393X

Saidova M.A.

Chazov National Medical Research Centre of Cardiology

ORCID: 0000-0002-3233-1862

Sergienko V.B.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0002-0487-6902

Tereshchenko S.N.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0001-9234-6129

Received:

05.02.2023

Accepted:

17.03.2023

Close metadata

References:

Alcantara M, Mezei MM, Baker SK, Breiner A, Dhawan P, Fiander A, Fine NM, Hahn C, Katzberg HD, Khayambashi S, Massie R, Matte G, Putko B, Siddiqi Z, Delgado D, Bril V. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Canadian Journal of Neurological Sciences. 2022;49(1):7-18. https://doi.org/10.1017/cjn.2021.34
Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. Journal of Clinical Pharmacy and Therapeutics. 2014;39:225-233. https://doi.org/10.1111/jcpt.12145
Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurology and Therapy. 2016;5(1):1-25. https://doi.org/10.1007/s40120-016-0040-x
Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurological Sciences. 2022;43(suppl 2):595-604. https://doi.org/10.1007/s10072-020-04889-2
Saidova MA, Sokhibnazarova VH, Avalyan AA, Tereshchenko SN. Comparative evaluation of speckle tracking echocardiography technologies in two-dimensional and three-dimensional modes in patients with chronic heart failure with preserved and reduced systolic function of the left ventricle. Russian Cardiology Bulletin, 2020:1:64-71. (In Russ.). https://doi.org/10.36396/MS.2020.16.1.009
The Human Gene Mutation Database. https://portal.biobase-international.com/hgmd/pro/gene.php?gene=ttr
Carroll A, Dyck PJ, de Carvalho M, Kennerson M, Reilly MM, Kiernan MC, Vucic SJ. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Journal of Neurology, Neurosurgery and Psychiatry. 2022;93(6):668-678. https://doi.org/10.1136/jnnp-2021-327909
Adyan TA, Polyakov AV. Hereditary transthyretin amyloidosis. Neuromuscular Diseases. 2019;9(4):12-25. (In Russ.). https://doi.org/10.17650/2222-8721-2019-9-4-12-25
Vita G, Mazzeo A, Di Leo R, Ferlini A. Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy. Neuromuscular Diseases. 2005;15(3):259-261. https://doi.org/10.1016/j.nmd.2004.10.015
Kawaji T, Ando Y, Ando E, Nakamura M, Hirata A, Tanihara H. A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathy. Amyloid. 2004;11:257-259. https://doi.org/10.1080/13506120400015580
Golbus JR, Wells JM, Dickinson MG, Hummel SL. Importance of Genetic Testing in the Diagnosis of Transthyretin Cardiac Amyloidosis. American Journal of Medicine. 2018;131(7):e303-4. https://doi.org/10.1016/j.amjmed.2018.02.005
Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, Kyriakides T; European Network for TTR-FAP (ATTReuNET). Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Current Opinion in Neurology. 2016;29:27-35. https://doi.org/10.1097/WCO.0000000000000290
Conceição I, Damy T, Romero M, Galán L, Attarian S, Luigetti M, Sadeh M, Sarafov S, Tournev I, Ueda M. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26:3-9. https://doi.org/10.1080/13506129.2018.1556156
Mandich P, Lamp M, Gotta F, Gulli R, Iacometti A, Marchese R, Bellone E, Abbruzzese G, Ferrandes G. 1993-2014: two decades of predictive testing for Huntington’s disease at the Medical Genetics Unit of the University of Genoa. Molecular Genetics and Genomic Medicine. 2017;5:473-480. https://doi.org/10.1002/mgg3.238
Tereshchenko SN, Zhirov IV, Moiseeva OM, Adasheva TV, Ansheles AA, Barbarash OL, Galyavich AS, Gudkova AJa, Zateyshchikov DA, Kostareva AA, Nasonova SN, Nedogoda SV, Pecherina TB, Ryzhkova DV, Sergienko VB. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Terapevticheskii Arkhiv. 2022;94(4):584-595. (In Russ.). https://doi.org/10.26442/00403660.2022.04.201465